Lantern Pharma Inc. (LTRN): Price and Financial Metrics

Lantern Pharma Inc. (LTRN): $9.65

0.13 (-1.33%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add LTRN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#192 of 363

in industry

LTRN Price/Volume Stats

Current price $9.65 52-week high $11.99
Prev. close $9.78 52-week low $2.38
Day low $9.65 Volume 1,146
Day high $9.65 Avg. volume 258,793
50-day MA $5.63 Dividend yield N/A
200-day MA $4.54 Market Cap 103.65M

LTRN Stock Price Chart Interactive Chart >


Lantern Pharma Inc. (LTRN) Company Bio


Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.


LTRN Latest News Stream


Event/Time News Detail
Loading, please wait...

LTRN Latest Social Stream


Loading social stream, please wait...

View Full LTRN Social Stream

Latest LTRN News From Around the Web

Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.

The 3 Most Undervalued AI Penny Stocks to Buy in December

It’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023. The AI market was worth roughly $515 billion in 2023. By 2030, it is expected to more than quadruple in value, reaching $2.025 trillion. That equates to a compound annual growth rate of more than 21% over the period. So, it’s easy to see why investors are scrambling to invest in undervalued penny in the

Yahoo | December 13, 2023

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

DALLAS, November 30, 2023--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.

Yahoo | November 30, 2023

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast […]

Yahoo | November 10, 2023

LTRN: Three Assets in the Clinic in 3Q:23

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Third Quarter 2023 Financial and Operational Results On November 8, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:23 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. Since Lantern’s second quarter update, it has added new sites in Asia for its

Yahoo | November 9, 2023

Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates

Advancements in Clinical Trials and AI Platform Highlighted Amid Financial Discipline

Yahoo | November 8, 2023

Read More 'LTRN' Stories Here

LTRN Price Returns

1-mo 114.44%
3-mo 125.47%
6-mo 182.99%
1-year 108.87%
3-year -46.66%
5-year N/A
YTD 125.47%
2023 -29.14%
2022 -24.31%
2021 -58.55%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!